Cytokinetics CYTK Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's stock-based comp?
- Cytokinetics (CYTK) reported stock-based comp of $30.39M in Q1 2026.
- How has Cytokinetics's stock-based comp changed year-over-year?
- Cytokinetics's stock-based comp increased by 29.1% year-over-year, from $23.55M to $30.39M.
- What is the long-term trend for Cytokinetics's stock-based comp?
- Over 4 years (2021 to 2025), Cytokinetics's stock-based comp has grown at a 43.0% compound annual growth rate (CAGR), from $26.83M to $112.29M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock.
- How do you interpret stock-based comp?
- High levels may indicate aggressive talent acquisition or dilution, while low levels may suggest cost control.
- How does stock-based comp compare across companies?
- Standard in high-growth biotech; often a significant portion of operating expenses.